GAITHERSBURG, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 1:30 p.m. ET in New York, NY.
About Sensei Biotherapeutics
Sensei Biotherapeutics is a
clinical-stage biopharmaceutical company developing precision
immuno-oncology therapies to transform the cancer treatment landscape.
The company is using its proprietary drug discovery platform, called
SPIRIT, to discover and develop both vaccines and T-cell therapies,
including SNS-301, its clinical stage cancer vaccine for the treatment
of head and neck cancer and myelodysplastic syndrome, as well as other
solid tumors and hematological cancers. SNS-301 targets a novel
embryonic antigen and has successfully completed a Phase 1 clinical
study. Sensei’s precision medicine approach in immuno-oncology includes
the use of companion diagnostics to select patients who are most likely
to respond to its tumor-specific antigen therapies. Sensei
Biotherapeutics is located in Gaithersburg, MD. For more information,
please visit www.senseibio.com.